


| Molecular Weight | 525.1 g/mol |
|---|---|
| Molecular Formula | C23H33ClN6O4S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 524.1972524 g/mol |
| Monoisotopic Mass | 524.1972524 g/mol |
| Topological Polar Surface Area | 118 A^2 |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 854 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Vardenafil hydrochloride |
| Drug Label | LEVITRA is an oral therapy for the treatment of erectile dysfunction. This monohydrochloride salt of vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).Vardenafil HCl is designated... |
| Active Ingredient | Vardenafil hydrochloride |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 2.5mg; 5mg; 10mg; 20mg |
| Market Status | Prescription |
| Company | Teva Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Vardenafil hydrochloride |
| Drug Label | LEVITRA is an oral therapy for the treatment of erectile dysfunction. This monohydrochloride salt of vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).Vardenafil HCl is designated... |
| Active Ingredient | Vardenafil hydrochloride |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 2.5mg; 5mg; 10mg; 20mg |
| Market Status | Prescription |
| Company | Teva Pharms |